

ICAR

Italian Conference on AIDS and Retroviruses

VI CONGRESSO NAZIONALE

Chairmen: M. Andreoni, A. Antinori, C.F. Perno



Promossa da
SIMIT
e da:
INMI, Istituto Nazionale per le Malattie Infettive
ISS, Istituto Superiore di Sanità
SIICA, Società Italiana di Immunologia, Immunologia Clinica e Allergologia
SIMaST, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili
SIV, Società Italiana di Virologia
SIVIM, Società Italiana di Virologia Medica
ANLAIDS, Associazione Nazionale per la lotta all'AIDS
ARCIGAY, Associazione LGBT Italiana
LILA, Lega Italiana per la lotta contro l'AIDS
NADIR, Fondazione Nadir Onlus
NPS Italia Onlus, Network Persone Sieropositive



ROMA, 25-27 MAGGIO 2014
SHERATON CONFERENCE CENTER

Elenco Oral Communication Selezionate

ID	N. PGM	Titolo	Presenting Author
26/05/2014 Antiretroviral therapy: randomized trials and clinical studies			
09.45 - 11.45			
68	OC 1	HIV Clinical Pathway in Lombardy Region: effects on professional practice, patients outcomes and treatment costs	Davide Croce, Castellanza
268	OC 2	Predictors of 24-weeks Treatment Failure in a Randomized Trial Comparing Switch to a Dual Therapy with Atazanavir/ritonavir + Lamivudine to continuation of Atazanavir/ritonavir + 2NRTIs in virologically suppressed HIV-infected patients	Massimiliano Fabbiani, Rome
155	OC 3	The LAREY study: Lamivudine/emtricitabine with unboosted Reyataz© for patients with long-lasting virological suppression	Alessia Carbone, Milano
291	OC 4	A randomized trial comparing DRV/r or LPV/r QD monotherapy with maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication: final results of the Protease Inhibitors MOnotherapy (PRIMO) Study	Carmela Pinnetti, Rome
120	OC 5	Dual regimen with darunavir/ritonavir 800/100 mg QD and either lamivudine or emtricitabine as maintenance therapy in HIV-infected patients with HIV-RNA <50 copies/mL	Nicola Gianotti, Milano
66	OC 6	Simplification therapy with lamivudine and boosted darunavir in a cohort of treatment-experienced HIV-infected patients	Alberto Borghetti, Rome
142	OC 7	Efficacy and tolerability of switching to a dual therapy with darunavir/r+raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL	Giordano Madeddu, Sassari
207	OC 8	Risk of discontinuation of first-line ritonavir-boosted protease inhibitor-based regimens	Giuseppe Lapadula, Monza
171	OC 9	Italian Observational study on the outcome of Atazanavir/ritonavir-based ARV therapies (SIMIT 001 Study): 3 years follow-up	Sergio Lo Caputo, Firenze
26/05/2014 Immunopathogenesis			
09.45 - 11.45			
261	OC 10	Impact of HIV-1 tropism on emergence of non-AIDS events in HIV-infected patients receiving a fully suppressive antiretroviral therapy (ARV)	Elisa Gentilotti, Rome
62	OC 11	Therapeutic immunization with HIV-1 Tat protein induces a restoration of immune homeostasis and attack the HAART-resistant blood HIV DNA: results from a randomized phase II clinical trial	Fabrizio Ensoli, Rome
50	OC 12	Extracellular HIV-1 Tat binds Env forming a novel virus entry complex that enhances HIV infectivity by targeting HIV to RGD-binding integrins: development of a novel neutralization assay which predicts DNA decay in blood	Aurelio Cafaro, Rome
27	OC 13	Altered monocyte phenotype and activation in HIV-infected patients with sub-optimal CD4+ T cell recovery during suppressive antiretroviral treatment	Davide Mangioni, Monza
222	OC 14	HIV infection modulates gut mucosal Vdelta1 and Vdelta2 T-cells differentiation profile and response	Eleonora Cimini, Rome
158	OC 15	Impact of CMV infection on soluble markers of myeloid activation in HIV infected subjects	Miriam Lichtner, Rome
63	OC 16	Impact of anti-Tat immunity on the immunological, virological and clinical outcome: a longitudinal cohort-study in cART-treated individuals	Antonella Tripiciano, Rome
26/05/2014 Epidemiology and prevention			
09.45 - 11.45			
89	OC 17	HIV-1 transmission networks in Italy: epidemiological characteristics and trend	Alessia Lai, Milan
283	OC 18	Prevalence of undiagnosed HIV in Italy at the end of 2012: an estimate based on surveillance data and disease stage	Alessia Mammone, Rome
119	OC 19	HIV rapid testing in community sites: results of a multicenter study in Italy	Giacomina Chiaradia, Rome
152	OC 20	Acute HIV infections in Rome, 2004-2013	Nicoletta Orchi, Rome
251	OC 21	Awareness and Use of HIV Pre-Exposure Prophylaxis in Italy: a nationwide cross-sectional study	Antonio Palummieri, Roma

ICAR

Italian Conference on AIDS and Retroviruses

VI CONGRESSO NAZIONALE

Chairmen: M. Andreoni, A. Antinori, C.F. Perno



e da:

INMI, Istituto Nazionale per le Malattie Infettive
ISS, Istituto Superiore di Sanità
SIICA, Società Italiana di Immunologia, Immunologia Clinica e Allergologia
SIMaST, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili
SIV, Società Italiana di Virologia
SIVIM, Società Italiana di Virologia Medica
ANLAIDS, Associazione Nazionale per la lotta all'AIDS
ARCIGAY, Associazione LGBT Italiana
LILA, Lega Italiana per la lotta contro l'AIDS
NADIR, Fondazione Nadir Onlus
NPS Italia Onlus, Network Persone Sieropositive



ROMA, 25-27 MAGGIO 2014
SHERATON CONFERENCE CENTER

Elenco Oral Communication Selezionate

ID	N. PGM	Titolo	Presenting Author
270	OC 22	Candidacy for TasP and PrEP in the PEP population: an analysis of the Italian Registry of Antiretroviral Post-Exposure Prophylaxis (IRAPEP)	Gabriella De Carli, Roma
284	OC 23	Acute HIV infection (AHI) in an infectious diseases specialized clinical setting: case-finding, description of virological, epidemiological, and clinical characteristics, as well as viral dynamics after cART	Adriana Ammassari, Roma
130	OC 24	Factors determining the Retention in Care in 798 persons living with HIV newly diagnosed at National Institute for Infectious Diseases "L. Spallanzani", Rome, in 2005-2011: a retrospective cohort study	Francesco Maria Fusco, Rome
33	OC 25	Increased incidence of Sexually Transmitted Diseases (STD) in the recent years: data from the ICONA cohort	Antonella Cingolani, Roma
26/05/2014 Coinfections 15.45 - 17.45			
255	OC 26	Use of triple therapy containing Telaprevir or Boceprevir in HCV-infected patients in clinical practice: preliminary comparison between HCV and HIV/HCV patients	Antonella Cingolani, Roma
218	OC 27	Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV-coinfected as compared to HCV-monoinfected patients	Alessandro Soria, Monza
75	OC 28	Treatment of HIV co-infected hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: efficacy results to week 16 on 45 Italian patients	Andrea Gori, Monza
73	OC 29	Development and Persistence of DAA Resistance Associated Mutations in Patient Failing Treatment.	Stefania Paolucci, Pavia
79	OC 30	Natural Resistance to NS3 Protease Inhibitors in Hepatitis C Genotype 1a clades 1 and 2 in HIV/HCV coinfected individuals	Sabrina Bagaglio, Milan
135	OC 31	Safety of Raltegravir-based regimen in an Italian cohort of HIV/HCV co-infected individuals.	Lucia Taramasso, Genova
91	OC 32	Liver disease severity and low bone mineral density in HIV-monoinfected and HIV/HCV co-infected patients	Paola Di Carlo, Palermo
54	OC 33	Lower Frequency of Circulating Central Memory T-cells and Increased Functional Capacity of HPV 16-specific CD8+ T-cells in HPV 16+, HIV-Infected Males	Camilla Tincati, Milan
11	OC 34	A new predictive model to improve respiratory isolation strategy in HIV patients with pulmonary tuberculosis	Manuela Carugati, Milan
26/05/2014 Viral and host mechanisms 15.45 - 17.45			
59	OC 35	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T cell decay and viral load and delay of disease progression: results of a 3 years cohort study	Stefania Bellino, Rome
100	OC 36	A regulatory polymorphism modulates TIM-3 expression and susceptibility to HIV-1 infection	Micaela Garziano, Milan
208	OC 37	Differential maturing level of NK cells derived from CD34+ cells circulating in peripheral blood of HIV infected patients compared to NK maturing from umbilical cord blood precursors	Federica Bozzano, Genoa
213	OC 38	Myeloid Derived Suppressor cells from HIV+ patients induce CD3ζ down-modulation on T cells by suppressing the transcription factor ELF-1	Alessandra Sacchi, Rome
247	OC 39	Markers of microbial translocation and inflammation in HAART responder subjects affected by Inflammatory Bowel Disease	Ivano Mezzaroma, Rome
189	OC 40	ERK based pathway as new selective mechanism for long lasting modulation of CCR5 by natural human antibodies	Assunta Venuti, Milan
95	OC 41	Elevated Interferon stimulated gene 15 levels are associated with high viral load and low CD4+ T-cell counts in chronically untreated HIV-1 infected patients	Carolina Scagnolari, Rome
122	OC 42	HIV-1 gp120 inhibits erythroid differentiation of CD34+ haematopoietic progenitor cells (HPCs)	Silvia Morini, Bologna

ICAR

Italian Conference on AIDS and Retroviruses

VI CONGRESSO NAZIONALE

Chairmen: M. Andreoni, A. Antinori, C.F. Perno



e da:

INMI, Istituto Nazionale per le Malattie Infettive
ISS, Istituto Superiore di Sanità
SIICA, Società Italiana di Immunologia, Immunologia Clinica e Allergologia
SIMaST, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili
SIV, Società Italiana di Virologia
SIVIM, Società Italiana di Virologia Medica
ANLAIDS, Associazione Nazionale per la lotta all'AIDS
ARCIGAY, Associazione LGBT Italiana
LILA, Lega Italiana per la lotta contro l'AIDS
NADIR, Fondazione Nadir Onlus
NPS Italia Onlus, Network Persone Sieropositive



ROMA, 25-27 MAGGIO 2014
SHERATON CONFERENCE CENTER

Elenco Oral Communication Selezionate

ID	N. PGM	Titolo	Presenting Author
26/05/2014 HIV infection and women 15.45 - 17.45			
297	OC 43	Who are the women presenting late at HIV-1 diagnosis?	Silvia Pittalis, Roma
56	OC 44	Featuring HIV/HCV coinfecting women in the Icona Cohort: epidemiological and clinical aspects according to gender.	Antonella Cingolani, Roma
29	OC 45	Improved healthcare strategy to treat HIV. A multidisciplinary approach by physicians and specialized pharmacist increases adherence to HAART and virologic suppression in a cohort of HIV-infected women	Nicolò Girometti, Bologna
299	OC 46	Persistence of HPV cervical infection and related factors in HIV positive women	Laura Comi, Milano
178	OC 47	The Implementation of Expanded PMTCT Programs: Experience from AMANI Study, Dodoma, Tanzania	Nazario Bevilacqua, Rome
193	OC 48	Nevirapine concentrations in Plasma, Cord Blood and Breast Milk from 135 HIV-infected women during pregnancy and breast feeding in Dodoma, United Republic of Tanzania	Massimo Tempestilli, Rome
205	OC 49	Spontaneous abortion in HIV-infected women: data based on women's self-report in the DIDI study	Adriana Ammassari, Roma
26/05/2014 Difficult clinical cases: the joint expertise of the virologist and the HIV specialist 18.00 - 19.15			
CR	OC 50	Regression of renal stones in HIV-1-infected patient after reduction of atazanavir dose	Massimiliano Lanzafame, Verona
CR	OC 51	Therapeutic intensification with raltegravir allows the achievement of virological success in a patient with prolonged and persistently low level viremia under standard HAART	Ada Bertoli, Roma
CR	OC 52	Poly-resistant disseminated tuberculosis with abdominal localization in a HIV/AIDS advanced naive patient	Giovanni Villa, Udine
CR	OC 53	Hemophagocytic syndrome in HIV acute infection: the role of mega-HAART	Silvia Costarelli, Monza
CR	OC 54	HBV/HCV/HDV coinfection in anti-HIV positive patient: Evaluation of reciprocal virological interactions in plasma, Peripheral Blood Mononuclear Cells (PBMCs) and liver tissue	Salvatore Martini, Napoli
27/05/2014 Antiretroviral therapy: observational studies 11.15 - 13.15			
106	OC 55	Determinants of the use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in the Icona Foundation Study	Alessandro Cozzi-Iepri, Londra
90	OC 56	Efavirenz to Rilpivirine switch with a common tenofovir/emtricitabine backbone in virologically controlled subjects	Elisa Di Filippo, Bergamo
294	OC 57	Switching to Rilpivirine/Emtricitabine/Tenofovir (EPA) from current antiretroviral regimen (cARV) in clinical practice: virologic failure and treatment discontinuation in a multicenter Italian cohort	Carmela Pinnetti, Rome
197	OC 58	Nevirapine + Abacavir/Lamivudine as switch therapy: data from a large national cohort	Renato Maserati, Pavia
159	OC 59	Efficacy, safety and laboratory changes in a cohort of HIV-infected patients starting abacavir/lamivudine and boosted darunavir: a retrospective, longitudinal study	Alberto Borghetti, Rome
143	OC 60	Short and long-term clinical outcomes and predictors after efavirenz (EFV) or boosted-PI containing HAART: results from the Italian MaSTER Cohort	Maria Concetta Postorino, Catanzaro
109	OC 61	Outstanding outcome: in whom and how	Franco Maggiolo, Bergamo
327	OC 62	There is an effective antiretroviral therapy in patients with high level of HIV-RNA >500.000 cp/ml? Preliminary data from 4 x High Study Group	Sergio Lo Caputo, Firenze
181	OC 63	Residual viremia: risk of virological rebound and evaluation of inflammation markers	Francesca Falasca, Rome

ICAR

Italian Conference on AIDS and Retroviruses

VI CONGRESSO NAZIONALE

Chairmen: M. Andreoni, A. Antinori, C.F. Perno



e da:

INMI, Istituto Nazionale per le Malattie Infettive
ISS, Istituto Superiore di Sanità
SIICA, Società Italiana di Immunologia, Immunologia Clinica e Allergologia
SIMaST, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili
SIV, Società Italiana di Virologia
SIVIM, Società Italiana di Virologia Medica
ANLAIDS, Associazione Nazionale per la lotta all'AIDS
ARCIGAY, Associazione LGBT Italiana
LILA, Lega Italiana per la lotta contro l'AIDS
NADIR, Fondazione Nadir Onlus
NPS Italia Onlus, Network Persone Sieropositive



ROMA, 25-27 MAGGIO 2014
SHERATON CONFERENCE CENTER

Elenco Oral Communication Selezionate

ID	N. PGM	Titolo	Presenting Author
27/05/2014 Basic and Clinical virology			
11.15 - 13.15			
172	OC 64	Excision of HIV-1 provirus as novel approach to eradicate the infection	Michele Lai, Pisa
240	OC 65	Autograft HIV-DNA load predicts peripheral HIV-1 reservoir size after autologous stem cell transplantation for AIDS related lymphoma patients	Stefania Zanussi, Aviano
253	OC 66	HIV DNA integration and replication in primary human macrophages and CD4+ T cells, in presence and absence of integrase inhibitors	Matteo Surdo, Rome
282	OC 67	HIV-1 integrase genotyping is reliable and clinically useful also in patients failing at low levels viremia	Maria Mercedes Santoro, Rome
173	OC 68	Analysis of intracellular human immunodeficiency virus (HIV)-1 drug resistance mutations in multi-failed HIV-1-infected patients treated with a salvage regimen: 3-years follow-up	Claudia Montagna, Rome
306	OC 69	Genotypic co-receptor tropism testing on HIV-1 DNA in virologically suppressed infected patients: feasibility and analysis of determinants of R5 virus: preliminary results from the GUSTA STUDY	Barbara Rossetti, Siena
307	OC 70	Comparison between three genotypic assays and phenotypic tropism testing in acutely HIV-1 infected	Elisa Rita Ceresola, Milano
74	OC 71	Molecular characterization of HIV-1 subtype C gp-120 regions potentially involved in virus adaptive mechanisms	Alessandra Cenci, Rome
286	OC 72	Virological Response and Resistance Profile in HIV-1 Infected Patients Starting a First Darunavir Containing Regimen in Clinical Practice	Domenico Di Carlo, Rome
27/05/2014 Comorbidities and ARV toxicities			
11.15 - 13.15			
249	OC 73	2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: the impact in a large HIV cohort	Giovanni Guaraldi, Modena
243	OC 74	Determinants of Renal Tubular Dysfunction in HIV-positive Patients of More than 50 Years-old	Letizia Marinaro, Torino
311	OC 75	Relationship between body mass index and bone mineral density in HIV-infected patients referred for DXA	Federico Lupi, Rome
134	OC 76	Ten Years of Follow up of Non AIDS Defining Malignancies Among HIV Infected Patients in the HAART Era	Tommaso Ascoli-bartoli, Rome
167	OC 77	Protease inhibitors based antiretroviral regimens are protective on HPV related cervical invasive and pre-invasive conditions	Giovanna Orlando, Milano
108	OC 78	Lumbar puncture before HAART introduction in HIV + antiretroviral naïve patients: viro-immunological characterization of patients with high cerebrospinal fluid (CSF) HIV RNA	Francesca Iannuzzi, Milan
192	OC 79	APRI and FIB-4 scores are not associated with neurocognitive impairment in HIV-infected persons	Raffaella Libertone, Rome
53	OC 80	Functionally distinct populations of HIV-specific CD4 and CD8 T-cells in HIV-positive cART-naïve subjects with and without neurocognitive impairment	Esther Merlini, Milan
199	OC 81	Prevalence of Multimorbidity in Early Vs Late presenters HIV patients	Stefano Zona, Modena
27/05/2014 Community based studies			
11.15 - 13.15			
174	OC 82	The European HIV Testing Week in Italy: an opportunity for diagnosis and prevention	Giulio Maria Corbelli, Roma
118	OC 83	Sex work and HIV risk perception: Clients' stories on LilaChat	Patrizia Perone, Como
221	OC 84	HCV/HIV testing and counselling during HIV testing week: low awareness and risk perception	Paola Zuccalà, Rome
51	OC 85	Health education and HIV test offer in a population of refugees and asylum seekers: an experience in Ferrara area.	Daniela Segala, Cona (fe)
330	OC 86	HIV test: which is your best? A National survey on testing preferences	Giulio Maria Corbelli, Roma

ICAR

Italian Conference on AIDS and Retroviruses

VI CONGRESSO NAZIONALE

Chairmen: M. Andreoni, A. Antinori, C.F. Perno



e da:

INMI, Istituto Nazionale per le Malattie Infettive
ISS, Istituto Superiore di Sanità
SIICA, Società Italiana di Immunologia, Immunologia Clinica e Allergologia
SIMaST, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili
SIV, Società Italiana di Virologia
SIVIM, Società Italiana di Virologia Medica
ANLAIDS, Associazione Nazionale per la lotta all'AIDS
ARCIGAY, Associazione LGBT Italiana
LILA, Lega Italiana per la lotta contro l'AIDS
NADIR, Fondazione Nadir Onlus
NPS Italia Onlus, Network Persone Sieropositive



ROMA, 25-27 MAGGIO 2014
SHERATON CONFERENCE CENTER

Elenco Oral Communication Selezionate

ID	N. PGM	Titolo	Presenting Author
198	OC 87	LILA Help Line. Report of six year activity, from 2008 to 2013	Giuseppina Giupponi, Como
137	OC 88	A qualitative analysis of counselling intervention on HIV-infected patients	Alessandra Bianchi, Milano
37	OC 89	Anthropological reading of poems written by guests of Lombardy HIV/AIDS Family Homes in the workshops of the project "La dimora del tempo sospeso (The hanging in time home)"	Laura Rancilio, Milano
293	OC 90	HIV stigma and discrimination in a sample of 522 HIV positive people, with a special focus on health services. Results from the project "Positive Practices"	Michele Breveglieri, Bologna